



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Standalone Unaudited Results for the Quarter Ended 30 September, 2020

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Sep-20 (Unaudited)	Quarter Ended 30-Jun-20 (Unaudited)	Quarter Ended 30-Sep-19 (Unaudited)	Year to date ended 30-Sep-20 (Unaudited)	Year to date ended 30-Sep-19 (Unaudited)	Year Ended 31-Mar-20 (Audited)
1 (a). Revenue from Operations	4,149.73	3,526.67	3,653.82	7,676.40	7,201.88	13,745.25
(b). Other Income	2.28	1.90	41.87	4.19	45.94	57.22
Total Revenue	4,152.01	3,528.57	3,695.69	7,680.59	7,247.82	13,802.47
2. Expenditure						
a) Cost of materials consumed	3,974.10	2,698.36	3,300.90	6,672.46	6,513.44	13,179.80
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	-243.35	574.69	29.85	331.35	-43.04	-618.06
d) Employee Costs	30.19	27.64	30.25	57.83	59.32	144.39
e) Interest	28.09	45.89	22.73	73.98	39.39	97.83
f) Depreciation & Amortisation expense	11.89	11.20	10.66	23.10	21.19	42.63
g) Other Expenses	122.70	64.25	86.24	186.95	187.67	376.16
3. Profit before exceptional & extraordinary items & tax	228.39	106.54	215.06	334.92	469.85	579.72
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	-1.20
5. Profit before extraordinary items & tax	228.39	106.54	215.06	334.92	469.85	578.52
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	228.39	106.54	215.06	334.92	469.85	578.52
8. Tax expense						
a) Current Tax	-70.91	-10.65	-52.51	-81.56	-116.30	-172.51
b) Deferred Tax	-13.53	-16.09	-12.29	-29.61	-16.28	17.69
Total Tax Expense	-84.44	-26.74	-64.80	-111.17	-132.58	-154.82
9. Profit (Loss) for the period after tax	143.95	79.80	150.26	223.75	337.27	423.70
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	143.95	79.80	150.26	223.75	337.27	423.70
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	4.66	2.58	4.86	7.24	10.92	13.71
b) Diluted	4.66	2.58	4.86	7.24	10.92	13.71



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Notes:

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 September, 2020.
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Friday, 13 November 2020 at the Corporate Office of the Company.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2020 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. The Company manufactures pharmaceutical chemicals, which is a single business segment.
6. Figures for the previous period have been regrouped / reclassified, wherever necessary.

**By order of the Board of Directors
For Samrat Pharmachem Limited**

Rajesh Mehta
Executive Director
DIN: 00216731



Place : Mumbai

Date : 13 November 2020



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Assets & Liabilities

PARTICULARS	(Rs. in lakhs) (Rs. in lakhs)	
	Standalone AS ON 30-Sep-20 Un-Audited	Standalone AS ON 31-Mar-20 Audited
ASSETS		
Non Current Assets		
Property, Plant and Equipment	718.05	718.15
Capital Work-in-progress	119.24	108.08
Intangible Assets	0.39	0.39
Intangible Assets under development	-	0
Financial Assets		
Investments	-	-
Loans	19.40	16.87
Deferred Tax Assets (Net)	-	-
Other Non-Current Assets	25.31	23.33
Total Non Current Assets	882.39	866.82
CURRENT ASSETS		
Inventories	1,519.84	1,876.74
Financial Assets		
Investments	0.10	0.10
Trade Receivables	2,966.29	2,781.28
Cash And Cash Equivalents	581.78	117.18
Loans	-	2.34
Other Financial Assets	-	-
Other Current Assets	36.30	190.40
Total Current Assets	5,104.31	4,968.04
Total- Assets	5,986.70	5,834.86
EQUITY AND LIABILITIES		
Equity		
Equity Share Capital	308.97	308.97
Other Equity	2,345.18	2,121.40
Total Equity	2,654.15	2,430.37
Non-Current Liabilities		
Financial Liabilities		
Borrowings	-	-
Provisions	-	-
Deferred Tax Liabilities (Net)	44.07	14.48
Other Long Current Liabilities	-	-
Total Non-Current Liabilities	44.07	14.48
Current Liabilities		
Financial Liabilities		
Borrowings	831.53	909.67
Trade Payables	2,321.16	2,314.61
Other Financial Liabilities	-	-
Other Current Liabilities	54.76	43.89
Provisions	81.03	121.84
Total Current Liabilities	3,288.48	3,390.01
Total Liabilities	5,986.70	5,834.86



[Handwritten signature]



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2020

(Rupees in Lakhs)

Particulars	Half year ended 30-Sep-2020 (Unaudited)	Half year ended 30-Sep-2019 (Unaudited)
A. CASH FLOW FROM OPERATING ACTIVITIES		
Profit / (Loss) before tax	334.93	469.86
Adjustments For :		
Depreciation and amortization expense	23.10	21.19
(Gain) /Loss on Sale/write off of property, plant and equipment and intangible assets, net	0.88	1.22
Finance Cost	73.98	39.39
Interest Income	-1.58	-2.54
Dividend Income on investments	0.00	0.00
Net loss arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net gain on sale of arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net (gain)/ loss on sale of financial assets measured at fair value through other comprehensive income	0.00	0.00
Gain On Sale of Investment in subsidiary	0.00	0.00
Provision/write off/ (reversal) for doubtful trade receivables / advances	0.00	6.38
Sundry balances written back, net	0.00	0.00
Provision in respect of losses of a subsidiary	0.00	0.00
Effect of exchange rate changes	0.00	0.00
	96.38	65.64
Operating Profit Before Working Capital Changes	431.31	535.50
Movements in working capital:		
(Increase) / decrease in inventories	356.90	-106.16
(Increase) / decrease in trade receivables	-185.01	-866.79
(Increase) / decrease in other assets	153.92	122.81
Increase / (decrease) in trade payables	6.55	141.81
Increase / (decrease) in other liabilities	40.84	56.57
Increase / (decrease) in provisions	0.00	0.00
	373.20	-651.76
Cash Generated From Operations	804.51	-116.26
Income Tax Paid (net of refund)	-123.11	-58.79
Net cash generated from operating activities (A)	681.40	-175.05
B. CASH FLOW FROM INVESTING ACTIVITIES		
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development)	-35.06	-94.26
Proceeds from disposal of property, plant and equipment and intangible assets	0.00	0.00
Loans / Inter corporate deposits given / placed	0.00	0.00
Loans / Inter corporate deposits received back / matured	0.00	0.00
Purchase of investments	0.00	0.00
Proceeds from sale / redemption of investments	0.00	0.00
Bank balances not considered as cash and cash equivalents		
Fixed deposits / margin money placed	-174.00	-68.00
Fixed deposits / margin money matured	0.00	0.00
Interest received	1.58	0.82
Dividend received	0.00	0.00
Net cash from investing activities (B)	-207.48	-161.45
	Continued ...	



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals


Particulars	30-09-2020 Rs.	30-09-2019 Rs.
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds From Issue of equity shares on exercise of stock options / share application money received	0.00	0.00
Proceeds from borrowings	-78.14	376.65
Repayment of borrowings	-31.21	34.56
Finance costs	-73.98	-39.39
Dividend paid	0.00	0.00
Dividend distribution tax	0.00	0.00
Net Cash from / (Used) In Financing Activities (C)	-183.33	371.82
NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)	290.59	35.33
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD (Opening Balance)	25.74	150.27
EFFECT OF EXCHANGE DIFFERENCES ON RESTATEMENT OF FOREIGN CURRENCY CASH AND CASH EQUIVALENTS	0.00	0.00
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (Closing Balance)	316.33	185.60

By order of the Board of Directors
For Samrat Pharmachem Limited

Rajesh Mehta
Executive Director
DIN: 00216731



Place : Mumbai
Date : 13 November 2020



Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla
Advisory & Regulatory

CA Nilesh Dedhia
Direct Tax & Litigation

CA Miral Nagda
Audit & Assurance


CA Nihar Dhorad
Indirect Tax & Litigation

Independent Auditor's Review Report on Unaudited Quarterly and Year-to-date Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

To the Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30th September, 2020 and year to date results for the period from 01 April 2020 to 30 September 2020 attached herewith being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
2. This statement is responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financials statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying unaudited financial results prepared in accordance with applicable Indian Accounting Standards (Ind AS) and other recognized accounting policies and practices has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 and rules made there under, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP
Chartered Accountants
Firm Reg: No.:109364W/W100143


CA. Miral H. Nagda
(Partner)
Membership No. 108135



UDIN: 20108135AAAACL4640
Place: Mumbai
Date: 13th November, 2020

Head Office : RNJ Corporate, 201, Jawohar Road, Ghatkopar (East), Mumbai - 400077, INDIA.
T : 022 6153 5500 / 2501 0700 | E : info@shahnsavla.com | W : www.shahnsavla.com